Civic Intelligence

The Institute for Psychiatric Neuroscience

EIN 45-2206152 • 501(c)3 • Nashville, TN

Profile

To carry out and support basic research related to Obsessive Compulsive Disorder OCD and Depression.

5887 Fredericksburg DriveNashville, TN 37215

none

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2025

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2025

Net Margin

Score unavailable

No value available

Net margin requires both revenue and expenses on the latest valid filing.

Source year 2025

Top Officer Pay

81st percentile

$0

Higher top officer pay than 81% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2025

Asset Growth

10th percentile

-100%

Faster asset growth than 10% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2024 to 2025

Revenue Growth

Score unavailable

No value available

A valid growth rate could not be computed from the available filing history.

Annualized from 2024 to 2025

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Down

$0

Down $39,682 (-100%) from 2022

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Down

$0

Down $39,682 (-100%) from 2022

Operations
Liabilities / RevenueScore unavailableNet MarginScore unavailable

Revenue

Down

$0

Down $300,000 (-100%) from 2022

Expenses

Down

$1,200

Down $306,475 (-100%) from 2022

Net Income

Up

-$1,200

Up $6,475 (+84%) from 2022

Trend Graphs

Balance Sheet Trend

Asset Growth10th percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

$300K$200K$100K$0-$100KAssets 2012: $85,814Liabilities 2012: $02012Assets 2013: $212,588Liabilities 2013: $0Net Assets 2013: $212,5882013Assets 2014: $70,933Liabilities 2014: $02014Assets 2015: $38,163Liabilities 2015: $150,0002015Assets 2016: $27,134Liabilities 2016: $0Net Assets 2016: $27,1342016Assets 2017: $33,014Liabilities 2017: $20,0002017Assets 2018: $56,616Liabilities 2018: $40,100Net Assets 2018: $16,5162018Assets 2019: $49,870Liabilities 2019: $70,100Net Assets 2019: -$20,2302019Assets 2020: $54,952Liabilities 2020: $70,100Net Assets 2020: -$15,1482020Assets 2021: $47,357Liabilities 2021: $0Net Assets 2021: $47,3572021Assets 2022: $39,682Liabilities 2022: $0Net Assets 2022: $39,6822022Assets 2025: $0Net Assets 2025: $02025

Highlighted filing

2025

Assets$0
Liabilities-
Net Assets$0
Open 2025 Filing

Operations Trend

Revenue GrowthScore unavailable

Revenue, expenses, and net income by year, with the latest filing highlighted.

$400K$200K$0-$200KRevenue 2012: $150,200Expenses 2012: $64,386Net Income 2012: $85,8142012Revenue 2013: $260,046Expenses 2013: $133,272Net Income 2013: $126,7742013Revenue 2014: $4,808Expenses 2014: $146,463Net Income 2014: -$141,6552014Revenue 2015: $25Expenses 2015: $182,795Net Income 2015: -$182,7702015Revenue 2016: $350,000Expenses 2016: $211,029Net Income 2016: $138,9712016Revenue 2017: $145,000Expenses 2017: $159,120Net Income 2017: -$14,1202017Revenue 2018: $200,000Expenses 2018: $196,498Net Income 2018: $3,5022018Revenue 2019: $199,000Expenses 2019: $235,746Net Income 2019: -$36,7462019Revenue 2020: $255,100Expenses 2020: $250,018Net Income 2020: $5,0822020Revenue 2021: $240,100Expenses 2021: $247,695Net Income 2021: -$7,5952021Revenue 2022: $300,000Expenses 2022: $307,675Net Income 2022: -$7,6752022Revenue 2025: $0Expenses 2025: $1,200Net Income 2025: -$1,2002025

Highlighted filing

2025

Revenue$0
Expenses$1,200
Net Income-$1,200
Open 2025 Filing

Filings

Most recent year

2025 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$0
Liabilities
-
Net assets
$0
Revenue
$0
Expenses
$1,200
Net income
-$1,200
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2025Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$0.01$0.01
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.40$0.00$0.40$3.00$3.08$0.08
2021XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.47$0.00$0.47$2.40$2.48$0.08
2020XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.55$0.70$0.15$2.55$2.50$0.05
2019Summary only. Only limited summary data is available for this year.$0.50$0.70$0.20$1.99$2.36$0.37
2018Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.57$0.40$0.17$2.00$1.96$0.04
2017Summary only. Only limited summary data is available for this year.$0.33$0.20$1.45$1.59$0.14
2016Summary only. Only limited summary data is available for this year.$0.27$0.00$0.27$3.50$2.11$1.39
2015Summary only. Only limited summary data is available for this year.$0.38$1.50$0.00$1.83$1.83
2014Summary only. Only limited summary data is available for this year.$0.71$0.00$0.05$1.46$1.42
2013Summary only. Only limited summary data is available for this year.$2.13$0.00$2.13$2.60$1.33$1.27
2012Summary only. Only limited summary data is available for this year.$0.86$0.00$1.50$0.64$0.86
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
May 1, 2024 to Apr 30, 2025
Signed
Jun 30, 2025
Return Version
2024v5.2
Mission and Program Overview

Mission

To carry out and support research related to Obsessive Compulsive Disorder OCD and Depression.

To carry out and support basic research related to Obsessive Compulsive Disorder OCD and Depression.

Program Services

DescriptionGrantsExpenses
OCD AND DEPRESSION ARE EMOTIONALLY DEVASTATING PSYCHIATRIC DISORDERS WITH SIGNIFICANT SOCIAL AND ECONOMIC COSTS. AN ESTIMATED 5 TO 6 MILLION PEOPLE IN THE UNITED STATES WILL SUFFER FROM OCD DURING THEIR LIFETIME. THE WORLD HEALTH ORGANIZATION HAS SAID THAT OCD IS AMONG THE 10 MOST DISABLING CONDITIONS IN THE WORLD. ONE PROBLEM IS THAT THE MEDICATIONS USED TO TREAT OCD CAN TAKE UP TO TWELVE WEEKS TO EXERT THEIR EFFECT, AND ONLY 30 PERCENT OF PATIENTS WILL RESPOND TO THEIR FIRST MEDICATION TRIAL. THIS MEANS THAT THOSE WHO DO NOT RESPOND MUST WAIT ANOTHER 12 WEEKS TO SEE IF THE SECOND MEDICATION HAS ANY BENEFIT. IT IS NOT UNCOMMON FOR PATIENTS TO HAVE 3-4 MEDICATION TRIALS TO FIND A TREATMENT THAT WORKS. PATIENTS WITH EXTREME SYMPTOMS MAY GIVE UP AND TAKE THEIR LIVES. IN FACT, 14-17 PERCENT OF OCD PATIENTS WILL ATTEMPT SUICIDE DURING THEIR LIFETIME. AN ESTIMATED 17-20 MILLION AMERICAN ADULTS WILL SUFFER FROM DEPRESSION EACH YEAR. SEVERELY DEPRESSED PATIENTS ALSO HAVE HIGH SUICIDE RATES. SUICIDE IS THE FIFTH LEADING CAUSE OF DEATH AMONG ADULT MALES, AND IS THE THIRD LEADING CAUSE OF DEATH FOR ALL YOUNG PEOPLE AGES 15-24. ONE REASON FOR THESE HIGH SUICIDE RATES IS THAT SIGNIFICANT PERCENTAGES OF PATIENTS WITH OCD AND DEPRESSION WILL NOT RESPOND TO TREATMENTS, IN PART BECAUSE WE DO NOT UNDERSTAND WHAT REALLY CAUSES THESE DISORDERS. THE IFPN HAS FUNDED RESEARCH RELATED TO THE NEUROBIOLOGY OF DEPRESSION IN THE PAST, AND MAINTAINED AN IN-HOUSE RESEARCH LABORATORY PROGRAM COMPLETING STUDIES ON THE NEUROBIOLOGY OF OCD THAT ORIGINATED AT VANDERBILT UNIVERSITY MEDICAL CENTER. OUR IN-HOUSE RESEARCH HAS BEEN A CONTINUATION OF WORK CARRIED OUT BY THE FOUNDER THAT WAS FUNDED THROUGH THE DEPARTMENT OF PSYCHIATRY AT VANDERBILT UNIVERSITY MEDICAL CENTER. WHILE SCIENTISTS ARE AWARE THAT A SPECIFIC CIRCUIT IN THE BRAIN INVOLVING THE PREFRONTAL CORTEX MAY BE INVOLVED IN THE PATHOPHYSIOLOGY OF OCD, WE DO NOT UNDERSTAND WHY THIS CIRCUIT IS ABERRANT, WHY MEDICATIONS KNOWN AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS, OR SSRI'S, THAT BLOCK THE INACTIVATION OF A NEUROTRANSMITTER CALLED SEROTONIN, ARE EFFECTIVE IN THE TREATMENT OF OCD, AND WHY PATIENTS MUST TAKE THESE MEDICATIONS FOR UP TO 12 WEEKS TO GET BENEFIT FROM THEM. THE PURPOSE OF THE PROGRAM WAS TO SHOW HOW SSRIS CHANGE THE ACTIVITY OF NERVE CELLS IN THE PREFRONTAL CORTEX SO THAT MORE TARGETED DRUG TREATMENTS MIGHT BE DEVELOPED THAT COULD NORMALIZE ACTIVITY IN THE OCD CIRCUIT AND REDUCE THE AMOUNT OF TIME THAT PATIENTS HAVE TO SUFFER, WAITING FOR THEIR SSRI TREATMENTS TO HAVE A BENEFIT. SUCH TARGETED MEDICATIONS COULD GREATLY IMPROVE THE TREATMENT AND QUALITY OF LIFE FOR THOSE SUFFERING FROM OCD. WE ATTEMPTED TO DETERMINE HOW THESE MEDICATIONS AFFECT THE OCD CIRCUIT USING AN ANIMAL MODEL IN WHICH WE STIMULATED SEROTONIN SIGNALING IN THE BRAIN. WE WANTED TO DETERMINE HOW DIFFERENT CELLS IN THE EMOTIONAL PREFRONTAL CORTEX RESPONDED TO INCREASED SEROTONIN STIMULATION. WE CHEMICALLY STIMULATED SEROTONIN RELEASE IN THE PREFRONTAL CORTEX THEN DETERMINED THE NUMBER OF NERVE CELLS THAT WERE SEROTONIN-ACTIVATED BY STAINING BRAIN SECTIONS FOR A PROTEIN CALLED FOS, THAT IS ASSOCIATED WITH NEURONAL ACTIVATION. WE WANTED TO DETERMINE HOW THAT ACTIVATION WAS AFFECTED BY SHORT-OR LONG-TERM SSRI TREATMENT. A PRELIMINARY STUDY FOUND THAT LONG TERM- BUT NOT SHORT-TERM SSRI TREATMENT DAMPENED PREFRONTAL-STIMULATED NEURONAL ACTIVITY. WE ALSO WANTED TO DETERMINE HOW DIFFERENT CELL TYPES IN THE PREFRONTAL CORTEX RESPONDED TO SEROTONIN STIMULATION, AND HOW THOSE RESPONSES WERE ALTERED BY SSRI TREAMENTS. IN OUR PRELIMINARY WORK WE FOUND THAT SEROTONIN AFFECTS THE PROCESSING NEURONS WITHIN THE PREFRONTAL CORTEX DIFFERENTLY THAN THEY AFFECT NEURONS THAT PROJECT FROM THE PREFRONTAL CORTEX TO OTHER BRAIN REGIONS. MORE RECENT ANALYSES HAVE RAISED QUESTIONS ABOUT THESE INITIAL FINDINGS. UNFORTUNATELY, OUR MOST IMPORTANT EXPERIMENT, A LARGE DEFINITIVE EXPERIMENT DESIGNED TO ADDRESS THESE QUESTIONS FAILED DUE TO AN INABILITY TO DETECT FOS PROTEIN IN THE BRAIN SECTIONS ABOVE BACKGROUND LEVELS OF STAINING. THE DATA THAT WE DO HAVE IS BEING ANALYZED TO DETERMINE IF THERE ARE ANY FINDINGS FROM THE STUDY THAT MIGHT BE PUBLISHABLE. ALL LABORATORY WORK ON ALL PROJECTS ENDED LAST FISCAL YEAR. THE LABORATORY IS NOW CLOSED AND THE INSTITUTE DISSOLVED LAST JULY.-$1,200
Compensation and Service Providers
Top Officer Pay81st percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
William A HewlettExecutive Director-$0--
John H SullivanSecretary-$0--
Roger A WarnkeTreasurer-$0--
Filing and Contact Details

Filer

Filer Name
The Institute for Psychiatric
EIN
45-2206152
Phone
6156651315
Address
5887 Fredericksburg Drive, Nashville, TN 37215

Signing Officer

Name
William Hewlett
Title
Executive Director
Signed
2025-06-30
Discuss with paid preparer
Yes

Preparer

Firm
Thomason Financial Resources
Address
1009 Harding Trace Ct, Nashville, TN 37221
Preparer
Kim Thomason
Phone
6154794770
Supplemental Narrative

Additional Explanations

Schedule A, Part I, Line 4

“While there was no contractual relationship with vanderbilt university hospital, the institute for psychiatric neuroscience has been completing ocd-related research that was initiated and carried out at vanderbilt university medical, center for 13 years and provdied financial support for depression research at the medical center for a number of years. No grants were made to the medical center over the 2024-25 fiscal year.”

Raw XML Appendix129 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0William Hewlett
IRS990EZ/BooksInCareOfDetail/PhoneNum06156651315
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt05887 Fredericksburg Drive
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0Nashville
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0TN
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd0372154817
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt030727
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-1200
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt01200
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/FinalReturnInd0X
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt030727
IRS990EZ/Form990TotalAssetsGrp/EOYAmt00
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt030727
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt030727
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt00.50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt10.10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt20.10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0William A Hewlett
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1John H Sullivan
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2Roger A Warnke
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Executive Dir.
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Treasurer
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0true
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherChangesInNetAssetsAmt0-29527
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0To carry out and support basic research related to Obsessive Compulsive Disorder OCD and Depression.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0OCD AND DEPRESSION ARE EMOTIONALLY DEVASTATING PSYCHIATRIC DISORDERS WITH SIGNIFICANT SOCIAL AND ECONOMIC COSTS. AN ESTIMATED 5 TO 6 MILLION PEOPLE IN THE UNITED STATES WILL SUFFER FROM OCD DURING THEIR LIFETIME. THE WORLD HEALTH ORGANIZATION HAS SAID THAT OCD IS AMONG THE 10 MOST DISABLING CONDITIONS IN THE WORLD. ONE PROBLEM IS THAT THE MEDICATIONS USED TO TREAT OCD CAN TAKE UP TO TWELVE WEEKS TO EXERT THEIR EFFECT, AND ONLY 30 PERCENT OF PATIENTS WILL RESPOND TO THEIR FIRST MEDICATION TRIAL. THIS MEANS THAT THOSE WHO DO NOT RESPOND MUST WAIT ANOTHER 12 WEEKS TO SEE IF THE SECOND MEDICATION HAS ANY BENEFIT. IT IS NOT UNCOMMON FOR PATIENTS TO HAVE 3-4 MEDICATION TRIALS TO FIND A TREATMENT THAT WORKS. PATIENTS WITH EXTREME SYMPTOMS MAY GIVE UP AND TAKE THEIR LIVES. IN FACT, 14-17 PERCENT OF OCD PATIENTS WILL ATTEMPT SUICIDE DURING THEIR LIFETIME. AN ESTIMATED 17-20 MILLION AMERICAN ADULTS WILL SUFFER FROM DEPRESSION EACH YEAR. SEVERELY DEPRESSED PATIENTS ALSO HAVE HIGH SUICIDE RATES. SUICIDE IS THE FIFTH LEADING CAUSE OF DEATH AMONG ADULT MALES, AND IS THE THIRD LEADING CAUSE OF DEATH FOR ALL YOUNG PEOPLE AGES 15-24. ONE REASON FOR THESE HIGH SUICIDE RATES IS THAT SIGNIFICANT PERCENTAGES OF PATIENTS WITH OCD AND DEPRESSION WILL NOT RESPOND TO TREATMENTS, IN PART BECAUSE WE DO NOT UNDERSTAND WHAT REALLY CAUSES THESE DISORDERS. THE IFPN HAS FUNDED RESEARCH RELATED TO THE NEUROBIOLOGY OF DEPRESSION IN THE PAST, AND MAINTAINED AN IN-HOUSE RESEARCH LABORATORY PROGRAM COMPLETING STUDIES ON THE NEUROBIOLOGY OF OCD THAT ORIGINATED AT VANDERBILT UNIVERSITY MEDICAL CENTER. OUR IN-HOUSE RESEARCH HAS BEEN A CONTINUATION OF WORK CARRIED OUT BY THE FOUNDER THAT WAS FUNDED THROUGH THE DEPARTMENT OF PSYCHIATRY AT VANDERBILT UNIVERSITY MEDICAL CENTER. WHILE SCIENTISTS ARE AWARE THAT A SPECIFIC CIRCUIT IN THE BRAIN INVOLVING THE PREFRONTAL CORTEX MAY BE INVOLVED IN THE PATHOPHYSIOLOGY OF OCD, WE DO NOT UNDERSTAND WHY THIS CIRCUIT IS ABERRANT, WHY MEDICATIONS KNOWN AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS, OR SSRI'S, THAT BLOCK THE INACTIVATION OF A NEUROTRANSMITTER CALLED SEROTONIN, ARE EFFECTIVE IN THE TREATMENT OF OCD, AND WHY PATIENTS MUST TAKE THESE MEDICATIONS FOR UP TO 12 WEEKS TO GET BENEFIT FROM THEM. THE PURPOSE OF THE PROGRAM WAS TO SHOW HOW SSRIS CHANGE THE ACTIVITY OF NERVE CELLS IN THE PREFRONTAL CORTEX SO THAT MORE TARGETED DRUG TREATMENTS MIGHT BE DEVELOPED THAT COULD NORMALIZE ACTIVITY IN THE OCD CIRCUIT AND REDUCE THE AMOUNT OF TIME THAT PATIENTS HAVE TO SUFFER, WAITING FOR THEIR SSRI TREATMENTS TO HAVE A BENEFIT. SUCH TARGETED MEDICATIONS COULD GREATLY IMPROVE THE TREATMENT AND QUALITY OF LIFE FOR THOSE SUFFERING FROM OCD. WE ATTEMPTED TO DETERMINE HOW THESE MEDICATIONS AFFECT THE OCD CIRCUIT USING AN ANIMAL MODEL IN WHICH WE STIMULATED SEROTONIN SIGNALING IN THE BRAIN. WE WANTED TO DETERMINE HOW DIFFERENT CELLS IN THE EMOTIONAL PREFRONTAL CORTEX RESPONDED TO INCREASED SEROTONIN STIMULATION. WE CHEMICALLY STIMULATED SEROTONIN RELEASE IN THE PREFRONTAL CORTEX THEN DETERMINED THE NUMBER OF NERVE CELLS THAT WERE SEROTONIN-ACTIVATED BY STAINING BRAIN SECTIONS FOR A PROTEIN CALLED FOS, THAT IS ASSOCIATED WITH NEURONAL ACTIVATION. WE WANTED TO DETERMINE HOW THAT ACTIVATION WAS AFFECTED BY SHORT-OR LONG-TERM SSRI TREATMENT. A PRELIMINARY STUDY FOUND THAT LONG TERM- BUT NOT SHORT-TERM SSRI TREATMENT DAMPENED PREFRONTAL-STIMULATED NEURONAL ACTIVITY. WE ALSO WANTED TO DETERMINE HOW DIFFERENT CELL TYPES IN THE PREFRONTAL CORTEX RESPONDED TO SEROTONIN STIMULATION, AND HOW THOSE RESPONSES WERE ALTERED BY SSRI TREAMENTS. IN OUR PRELIMINARY WORK WE FOUND THAT SEROTONIN AFFECTS THE PROCESSING NEURONS WITHIN THE PREFRONTAL CORTEX DIFFERENTLY THAN THEY AFFECT NEURONS THAT PROJECT FROM THE PREFRONTAL CORTEX TO OTHER BRAIN REGIONS. MORE RECENT ANALYSES HAVE RAISED QUESTIONS ABOUT THESE INITIAL FINDINGS. UNFORTUNATELY, OUR MOST IMPORTANT EXPERIMENT, A LARGE DEFINITIVE EXPERIMENT DESIGNED TO ADDRESS THESE QUESTIONS FAILED DUE TO AN INABILITY TO D
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt01200
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt01200
IRS990EZ/TotalProgramServiceExpensesAmt01200
IRS990EZ/TotalRevenueAmt00
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0None
IRS990ScheduleA/Form990ScheduleAPartVIGrp/ExplanationTxt0WHILE THERE IS NO CONTRACTUAL RELATIONSHIP WITH VANDERBILT HOSPITAL, THE INSTITUTE FOR PSYCHIATRIC NEUROSCIENCE IS COMPLETING OCD-AND DEPRESSION-RELATED RESEARCH THAT WAS INITIATED AND CARRIED OUT FOR 13 YEARS AT VANDERBILT UNIVERSITY MEDICAL CENTER. THE IFPN ALSO PROVIDED FINANCIAL SUPPORT FOR DEPRESSION-RELATED RESEARCH AT THE MEDICAL CENTER FOR MANY YEARS IN THE PAST. NO GRANTS WERE MADE TO THE MEDICAL CENTER OVER THE 2023-24 FISCAL YEAR.
IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc0Part I: Additional Information
IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc1Part I, Line 12f: Supported Org Not Named in Organizing Documents
IRS990ScheduleA/HospitalNameAndAddressGrp/CityNm0Nashville
IRS990ScheduleA/HospitalNameAndAddressGrp/StateAbbreviationCd0TN
IRS990ScheduleA/HospitalNameAndAddressGrp/SupportedOrganizationName/BusinessNameLine1Txt0See Schedule O
IRS990ScheduleA/MedicalResearchOrganizationInd0X
IRS990ScheduleN/AssetsDistributedInd0true
IRS990ScheduleN/AttorneyGeneralNotifiedInd0true
IRS990ScheduleN/BondLiabilitiesDischargedInd0false
IRS990ScheduleN/BondsOutstandingInd0false
IRS990ScheduleN/DirectorOfSuccessorInd0false
IRS990ScheduleN/EmployeeOfSuccessorInd0false
IRS990ScheduleN/LiabilitiesPaidInd0true
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/AssetsDistriOrExpnssPaidDesc0Cash
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/DistributionDt02024-05-29
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/EIN0250965591
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/FairMarketValueOfAssetAmt029527
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/IRCSectionTxt0501 c 3
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/MethodOfFMVDeterminationTxt0Cash
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/AddressLine1Txt03600 Forbes Ave Suite 8084
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/CityNm0Pittsburgh
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/StateAbbreviationCd0PA
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/ZIPCd015213
IRS990ScheduleN/OwnerOfSuccessorInd0false
IRS990ScheduleN/ReceiveCompensationInd0false
IRS990ScheduleN/RequiredToNotifyAGInd0true
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0WHILE THERE WAS NO CONTRACTUAL RELATIONSHIP WITH VANDERBILT UNIVERSITY HOSPITAL, THE INSTITUTE FOR PSYCHIATRIC NEUROSCIENCE HAS BEEN COMPLETING OCD-RELATED RESEARCH THAT WAS INITIATED AND CARRIED OUT AT VANDERBILT UNIVERSITY MEDICAL, CENTER FOR 13 YEARS AND PROVDIED FINANCIAL SUPPORT FOR DEPRESSION RESEARCH AT THE MEDICAL CENTER FOR A NUMBER OF YEARS. NO GRANTS WERE MADE TO THE MEDICAL CENTER OVER THE 2024-25 FISCAL YEAR.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Schedule A, Part I, Line 4
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0William Hewlett
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Executive Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-06-30
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0The Institute for Psychiatric
ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt0Neuroscience
ReturnHeader/Filer/BusinessNameControlTxt0INST
ReturnHeader/Filer/EIN0452206152
ReturnHeader/Filer/PhoneNum06156651315
ReturnHeader/Filer/USAddress/AddressLine1Txt05887 Fredericksburg Drive
ReturnHeader/Filer/USAddress/CityNm0Nashville
ReturnHeader/Filer/USAddress/StateAbbreviationCd0TN
ReturnHeader/Filer/USAddress/ZIPCd037215
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0true
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0331040094
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0Thomason Financial Resources
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt01009 Harding Trace Ct
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0Nashville
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0TN
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd037221
ReturnHeader/PreparerPersonGrp/PhoneNum06154794770
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0Kim Thomason
ReturnHeader/ReturnTs02025-06-30T09:49:49-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-05-01
ReturnHeader/TaxPeriodEndDt02025-04-30
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.